RT Journal Article
SR Electronic
A1 Alexander, Lori
T1 Rivaroxaban of Benefit in STEMI: ATLAS ACS 2-TIMI 51
JF MD Conference Express
YR 2012
FD SAGE Publications
VO 12
IS 13
SP 24
OP 25
DO 10.1177/155989771213016
UL http://mdc.sagepub.com/content/12/13/24.abstract
AB Treatment with a low dose of rivaroxaban, an oral factor Xa inhibitor, has been shown to reduce recurrent cardiovascular (CV) events and offer a survival benefit without a significant increase in fatal bleeding for patients who have had an ST-segment elevation myocardial infarction. Rivaroxaban reduced recurrent CV events across the spectrum of acute coronary syndrome in the Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome—Thrombolysis in Myocardial Infarction 51 [ATLAS ACS 2-TIMI 51; J Mega et al. N Engl J Med 2012] trial.